JAK inhibition differentially affects NK cell and ILC1 homeostasis by Vian, L. et al.
ORIGINAL RESEARCH
published: 19 December 2019
doi: 10.3389/fimmu.2019.02972
Frontiers in Immunology | www.frontiersin.org 1 December 2019 | Volume 10 | Article 2972
Edited by:
Yenan Bryceson,
Karolinska Institutet (KI), Sweden
Reviewed by:











†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
NK and Innate Lymphoid Cell Biology,
a section of the journal
Frontiers in Immunology
Received: 05 August 2019
Accepted: 03 December 2019
Published: 19 December 2019
Citation:
Vian L, Le MT, Gazaniga N, Kieltyka J,
Liu C, Pietropaolo G, Dell’Orso S,
Brooks SR, Furumoto Y, Thomas CJ,
O’Shea JJ, Sciumè G and Gadina M
(2019) JAK Inhibition Differentially




JAK Inhibition Differentially Affects
NK Cell and ILC1 Homeostasis
Laura Vian 1, Mimi T. Le 1, Nathalia Gazaniga 1, Jacqueline Kieltyka 1, Christine Liu 1,
Giuseppe Pietropaolo 2, Stefania Dell’Orso 3, Stephen R. Brooks 4, Yasuko Furumoto 1,
Craig J. Thomas 5,6, John J. O’Shea 7, Giuseppe Sciumè 2*† and Massimo Gadina 1*†
1 Translational Immunology Section, Office of Science and Technology, National Institute of Arthritis Musculoskeletal and Skin
Diseases, National Institutes of Health, Bethesda, MD, United States, 2 Laboratory Affiliated to Istituto Pasteur
Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, 3Genomic
Technology Section, Office of Science and Technology, National Institute of Arthritis Musculoskeletal and Skin Diseases,
National Institutes of Health, Bethesda, MD, United States, 4 Biodata Mining and Discovery Section, Office of Science and
Technology, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD,
United States, 5Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of
Health, Bethesda, MD, United States, 6 Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of
Health, Bethesda, MD, United States, 7Molecular Immunology and Inflammation Branch, National Institute of Arthritis, and
Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, United States
Janus kinase (JAK) inhibitors are widely used in the treatment of multiple autoimmune and
inflammatory diseases. Immunologic and transcriptomic profiling have revealed major
alterations on natural killer (NK) cell homeostasis associated with JAK inhibitions, while
information on other innate lymphoid cells (ILCs) is still lacking. Herein, we observed that,
in mice, the homeostatic pool of liver ILC1 was less affected by JAK inhibitors compared
to the pool of NK cells present in the liver, spleen and bone marrow. JAK inhibition
had overlapping effects on the transcriptome of both subsets, mainly affecting genes
regulating cell cycle and apoptosis. However, the differential impact of JAK inhibition was
linked to the high levels of the antiapoptotic gene Bcl2 expressed by ILC1. Our findings
provide mechanistic explanations for the effects of JAK inhibitors on NK cells and ILC1
which could be of major clinically relevance.
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HIGHLIGHTS
- JAK inhibition has distinct impacts on the homeostatic numbers of NK cells and ILC1.
- Tofacitinib has redundant effects on the transcriptomic programs of NK cells and ILC1.
- Basal expression level of Bcl2 underlies the differential impact of tofacitinib in NK cells and ILC1.
INTRODUCTION
Cytokines are pivotal in the maintenance of an appropriate immune system homeostasis, but
dysregulation of their activity underlies multiple immune-related disorders (1). The elucidation
of the role of the Janus kinase (JAK) family of intracellular tyrosine kinases in the signaling
cascade downstream of cytokine receptors has highlighted this class of molecules as potential
therapeutic targets. Indeed, inhibition of JAK enzymatic activity has proved successful for several
immune-mediated pathologies and these drugs are now approved and prescribed to thousands of
patients around the world (2). Given the clinical relevance of the drugs that target these enzymes,
Vian et al. JAK Signals Regulate NK-ILC1 Homeostasis
more complete knowledge is clearly needed. As such, the
pharmacological manipulation of JAKs represents an interesting
strategy to study the homeostatic requirements of cytokine
signals in different immune cell types ranging from T and B cells
to innate lymphoid cells (ILCs).
ILCs provide rapid immune protection through an array
of effector functions mirroring those associated with T cells
(3). Based on this similarity, ILCs have been divided into five
prototypical subsets: natural killer (NK) cells, ILC1, ILC2, ILC3,
and lymphoid tissue inducer cells (3). NK cells and ILC1 are able
to quickly release the signature cytokine interferon (IFN)-γ and,
for this reason, were initially included within the group of type-1
ILCs (4, 5). The ontogeny of ILC1 and NK cells is thought to have
both overlapping and independent routes (6, 7); among the latter,
evidence in mice shows a distinct usage of T-box transcription
factors with a selective expression and function for Eomes in NK
cells in contrast to a specific requirement for T-bet in ILC1 (8).
In the context of ILC biology, JAK inhibitors (JAKinibs)
have been employed to track different functional outputs,
including cytokine production and cell proliferation upon
cytokine stimulation in vitro (9). Notably, when used in vivo,
JAKinibs have led to a reduction of the number of mouse NK
cells (10). Likewise, patients treated with JAKinibs display a dose-
dependent loss of peripheral blood NK cells (11–13). However,
no information is currently available about the effects of in vivo
treatment of JAKinibs on the phenotype of NK cells or other ILCs
in distinct tissues.
Development and homeostasis of both NK cells and ILC1
depend on the functions of cytokines, primarily IL-15 and
IL-7, which signal through the JAK/STAT pathway (14–16).
Observations in humans, corroborated by studies using animal
models, have shed light on the importance of the downstream
signaling events induced upon activation of JAK3, JAK1, and
STAT5 in the development and effector functions of ILCs (17).
In this regard, patients carrying JAK3 mutations develop severe
combined immunodeficiency associated with loss of T and NK
cells as well as the entire ILC system (18, 19). In mice, Jak3
deficiency blocks NK/ILC differentiation in the bone marrow
(BM) at the ILC precursor and the pre-NK cell progenitor stage;
thus, no ILCs are preserved in these mice (20). Similarly, ablation
of both Stat5a and Stat5b leads to almost total loss of NK cells
(21). This phenotype is also observed when the entire Stat5 locus
or Jak1 are deleted in Ncr1-expressing cells (22, 23). Selective
preservation of Stat5 alleles (Stat5b or Stat5a) has revealed a
critical role of Stat5b more so than Stat5a in regulating ILC
functions (24, 25), as well as a differential susceptibility among
ILCs to tolerate deprivation of STAT5 signals, with NK cells
and ILC1 being the most sensitive (25). The profound effects
on lymphoid development leading to loss of ILC populations
reveal a major limitation in using Jak3, Jak1, and Stat5 deficient
mice. Because many of the downstream effects of the JAK/STAT
pathway affect the functions of the immune system, distinct
compounds capable of blocking JAK enzymatic activity have
been developed as selective immunosuppressant to be used in
immune-mediated diseases (26).
Herein, we studied the impact of JAKinibs on the homeostasis
of two prototypical ILC subsets: NK cells and ILC1. We assessed
the effects of in vivo administration of a JAK1/3 inhibitor,
tofacitinib, vs. a more selective JAK3 inhibitor, PF-06651600,
focusing on NK cells from spleen, liver and BM and ILC1 from
liver. Our data revealed differential effects of these JAKinibs
on the NK cell and ILC1 numbers, the latter subset being less
sensitive to JAK inhibition. By using a transcriptomic approach,
we identified a major cell cycle block in both subsets after
in vivo treatment with tofacitinib, associated with a decreased
expression of antiapoptotic genes, including Bcl2. By using
a pharmacological approach, we demonstrated that the high
expression levels of Bcl2 in ILC1 were associated with the
differential impact of JAK inhibition observed between the two
subsets, arguing for divergent dependence of the homeostasis of
these populations on cytokine signals.
MATERIALS AND METHODS
Mice and Inhibitors
BALB/c and Rag2−/− mice were purchased from Jackson
Laboratory. All animal studies were performed according to
NIH guidelines for the use and care of live animals and were
approved by the NIAMS Institutional Animal Care and Use
Committee. JAKinibs were resuspended in 0.5% methyl cellulose
and animals were dosed orally twice daily with vehicle or 30
mg/kg of tofacitinib (kindly provided by Pfizer) or 20 mg/kg of
PF-06651600 (provided by the National Center for Advancing
Translational Sciences (NCATS), NIH) for 1 week (or 3 days,
where indicated) (27). ABT-199 (Venetoclax, Selleckchem) was
resuspended in 60% Phosal 50PG, 30% PEG 400, and 10% EtOH.
Animals were dosed orally once a day with vehicle or 90 mg/kg
for a week.
Cell Isolation, Flow Cytometry, and Cell
Activation Assays
Cells from spleen, liver and BM were isolated as previously
described (28). Antibodies are listed in Supplemental Figure 1.
Samples were acquired using LSR Fortessa cytometer
(BD Biosciences) and BD FACSDiva software (v.8.0.1, BD
Biosciences) and analyzed with FlowJo software (Tree Star). Cell
sorting was performed using FACSAria III (BD Biosciences). For
the evaluation of IFN-γ expression, cells were left untreated or
stimulated with PMA/Ionomycin (Sigma-Aldrich) for 2 h or IL-2
(1,000 U/ml, Hoffmann-La Roche Inc.) and IL-12 (10 ng/ml), or
IL-12 (10 ng/ml) and IL-18 (100 ng/ml) (R&D Systems) for 6 h
(with the addition of GolgiPlug, from BD Biosciences).
RNA Sequencing and Transcriptomic
Analysis
Cells isolated from spleen and liver were sorted (95–99%
post-sort purity) as described in Supplemental Figures 1A,B.
RNA-seq was performed according to manufacturer’s protocol
(NEBNext Ultra II RNA Library Prep, E7770L). Barcoded
sequencing libraries were sequenced on Illumina HiSeq3000. 50-
bp single end reads were demultiplexed to FastQ using bcl2fastq
2.17.1 and mapped onto mouse genome build mm10 using
TopHat 2.1.1. Gene expression values (RPKM, reads per kilobase
exon per million mapped reads) were calculated with Partek
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Genomic Suites 7.18.0723. RPKM values were log2 transformed
(with a 0.1 offset) and ANOVA was performed to find
differentially expressed genes. Expressed genes having an average
absolute RPKM > 2 were listed in Supplemental Tables 1, 2
for NK and ILC1, respectively (miRs and Snors were excluded)
and used for further analyses. Volcano plots were generated
using R 3.6.0; heatmaps were generated usingMorpheus software
(Broad Institute). DAVID bioinformatics resource was used for
GO analysis.
Statistics
Unpaired t-test and ANOVA were used to quantify statistical
deviation between experimental groups, as indicated in figure
legends. Asterisks denote significant differences ∗P < 0.05; ∗∗P
< 0.01; ∗∗∗P < 0.001.
RESULTS
Distinct Impact of JAK Inhibition on ILC1
and NK Cell Homeostatic Numbers
Immunologic and transcriptomic analysis performed on a wide
range of adaptive and innate immune cells inmice have revealed a
major impact of JAKinibs on the homeostatic pool of splenic NK
cells (10). Building on these findings, we sought to dissect how
prototypical liver ILC1 were affected by JAKinibs in relations to
NK cells present in the liver, spleen and BM.
We used, as a model, mice treated with oral administration
of a JAK1/3 or JAK3/TEC family (29) kinase-selective inhibitors,
tofacitinib and PF-06651600, respectively, for a week, twice daily
at doses comparable to the range approved for clinical use and
which do not provide a total block of JAK3/1 activity (10). We
analyzed lymphocytes isolated from liver, spleen and BM by flow
cytometry and assessed the relative number of NKp46+ cells
(gating strategies in Supplemental Figure 1A). Treatment with
both JAKinibs led to a marked and significant reduction of the
number (represented as ratio relative to control) of NKp46+
cells in all tissues analyzed (Figure 1A). Whereas, splenic and
BM NKp46+ cells mainly comprise NK cells, the liver contains
similar proportions of tissue resident ILC1 and NK cells. When
we dissected liver NKp46+ cells by CD49b (DX5) and Eomes
expression, we observed profound and significant changes of
NK/ILC1 ratios (Figure 1B). This phenotype was associated with
a differential effect in maintaining the homeostatic pools of ILC1
and NK cells. Indeed, while both NK cell and ILC1 numbers
were reduced, NK cells were affected to a greater degree than
ILC1 (Figure 1C and Supplemental Figure 1B). The differential
impact of JAK inhibition on NK cells and ILC1 was independent
by the presence of T and B lymphocytes, since similar results were
obtained inRag2−/− mice (Supplemental Figure 1C). Moreover,
while evidence proving a similar efficacy of inhibiting JAK3 alone
or both JAK1 and JAK3 has remained controversial (10, 30), our
results showed that selectively targeting JAK3 (and TEC kinases),
with PF-06651600, was as efficient as targeting multiple JAKs
using tofacitinib in terms of their impact on the homeostatic
pools of NKp46+ cells.
Together with the effects in liver and spleen, our data provided
evidence for the impact of JAKinibs on the pool of BM NK cells
FIGURE 1 | Effects of tofacitinib and PF-06651600 on ILC1, NK cells, and BM
progenitors. BALB/c mice were dosed orally with tofacitinib, PF-06651600 or
vehicle twice a day for 7 days. (A) Relative cell numbers for CD3ε− NKp46+
cells from liver (left panel), spleen (middle panel) and BM (right panel) are
shown. ANOVA one-way test was applied. (B) Subsets of liver NKp46+ cells
were distinguished by the expression of Eomes and DX5/CD49b. ILC1 were
defined as DX5−Eomes− cells and NK cells as DX5+Eomes+ cells.
Percentages depicted in dot plots are representative. (C) Relative cell numbers
for liver ILC1 and NK cells are shown. ANOVA one-way test was applied.
(A–C) Five independent experiments were combined, and values were
normalized to the mean of vehicle-treated mice in the corresponding
experiment. (D) Relative cell numbers of HSC, CLP, ILCp, and NKP
progenitors are shown. Student’s t-test statistics are comparing samples to
vehicle. Three independent experiments were combined, and values were
normalized to the mean of vehicle-treated mice for each
corresponding experiment. *P < 0.05; **P < 0.01; ***P < 0.001.
(Figure 1A), which led us to evaluate whether JAK inhibition
affected NK cell/ILC progenitors present in this tissue. As shown
in Figure 1D (gating strategies in Supplemental Figure 1D),
treatment with tofacitinib resulted in decreased numbers of HSC,
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CLP, and ILCp, as well as an accumulation of NKP, pointing
to a developmental block at this stage. These findings were in
agreement with a previous report showing that selective ablation
of the Stat5 locus in NK cells led to increased numbers of
NKP (22).
Altogether, our data showed that administration of JAKinibs
at doses within the range approved for clinical use, affected
the homeostatic pool of both ILC1 and NK cells, although the
impact of JAK inhibition was greater on NK cells. This effect
was independent from the presence of adaptive immune cells. In
addition, we showed that the effects of tofacitinib extended to BM
precursors and ILC/NK progenitors.
Tofacitinib Administration Inhibits the
Expression of Genes Regulating Cell Cycle
and Survival in NK Cells
We have previously shown that NK cells with reduction in Stat5b
or Stat5a levels exhibit a loss of their signature traits associated
with a maturation block (25). Therefore, we investigated whether
treatment with JAKinibs could also affect NK cell identity
and/or differentiation by coupling transcriptomic analysis and
flow cytometry.
At the transcriptional level, we observed that the impact
of the 7-days treatment with tofacitinib mainly consisted of a
FIGURE 2 | Impact of tofacitinib on the transcriptome and phenotype of splenic NK cells. (A) Volcano plot for genes expressed by splenic NK cells isolated from mice
treated or not for 1 week with tofacitinib. Representative down-regulated (blue) and up-regulated (red) genes are highlighted. Two mice for treated and three for vehicle
were pooled together for each replicate. (B) MA plot shows transcript abundance (x axis, mean RPKM in NK cells receiving vehicle) and FC (y axis, log2 of tofacitinib
÷ vehicle) for genes associated with NK cell identity. (C) Relative cell number for splenic NKp46+ and (D) NK cell subsets, defined by CD27, CD11b, or KLRG1
expression, at 3 and 7 days of tofacitinib treatment are shown. (E) Expression levels evaluated by flow cytometry for Ki67 (percentage of positive cells), Bcl2 [Mean
Fluorescence Intensity (MFI)], and CD98 (MFI) in NK cells at 3 and 7 days of tofacitinib treatment are shown. (C–E) Statistics were performed using one-way ANOVA.
Two independent experiments were combined (vehicle n = 8; 3-days treatment n = 5; 7-days treatment n = 6), and values were normalized to the mean of
vehicle-treated mice for each corresponding experiment. *P < 0.05; **P < 0.01; ***P < 0.001.
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reduction in gene expression in splenic NK cells (Figure 2A
and Supplemental Table 1), which included down-regulation of
genes involved in NK cell survival (Bcl2 and Bcl2l1), proliferation
(Mki67), and function (Gzmb), in agreement with a previous
report (10). On the other hand, genes defining NK cell identity
[gene list described by the Immgen project (31)] were not
affected by the treatment, except for Gzmb, which was the only
down-regulated gene with a fold-change (FC) higher than 2
(Figure 2B). Similarly, no significant differences in Eomes and
Tbx21 (encoding T-bet) were observed after in vivo treatment
with tofacitinib.
To evaluate the effect of tofacitinib treatment on terminal
differentiation, we measured the number of NK cells expressing
markers associated with distinct maturation stages, namely
CD27, CD11b, and KLRG1 (32, 33). To rule out the effects
of possible mechanisms of cell adaptation or selection which
could occur after the 7-days treatment, mice also received
the drug for only 3 days. As shown in Figure 2C, NK cell
numbers already started to decrease at the early time point,
and to a greater extent at day 7. This reduction was associated
with a global alteration of all the NK cell subsets analyzed
(Figure 2D), and led, after 7 days of treatment, to a selective
decrease of the frequency of terminally differentiated NK cells
expressing KLRG1 (Supplemental Figure 2), suggesting that
JAK inhibition could have cumulative effects during time either
on differentiation or turn-over of this subset.
Finally, we evaluated by flow cytometry the expression
levels of selected downregulated genes present in our dataset
(Supplemental Table 1), including Ki67 (encoded by Mki67) to
track cell cycle, Bcl2 for survival and CD98 (as a surrogate for
Slc7a5 expression). As shown in Figure 2E, expression of these
proteins was significantly affected both at day 3 and 7 after
tofacitinib treatment. Among all the parameters analyzed, only
Bcl2 was downregulated at higher degree at day 3 than day 7,
suggesting that the effect on survival could occur earlier than the
effects on proliferation and differentiation.
FIGURE 3 | Redundant effect of tofacitinib on ILC1 and NK cell transcriptomes. (A) Volcano plot for genes expressed by liver ILC1 isolated from mice treated or not
for 1 week with tofacitinib. Representative down-regulated (blue) and up-regulated (red) genes are highlighted. (B) Scatter plot comparing the effects of tofacitinib on
NK and ILC1. Genes significantly (p < 0.05) up-regulated (FC > 2) and down-regulated (FC < 0.5) in ILC1 are highlighted in red and blue, respectively. (C) Expression
of selected genes in liver and splenic NK cells is depicted by heatmap, comparing mice administered with vehicle or tofacitinib. (D) Forty-five down-regulated genes in
ILC1 having RPKM > 5; FC < 0.5; p-value < 0.05 were selected for GO. Only GO terms with a p-value < 0.05 are represented. More than 10 mice for each group
(vehicle and tofacitinib) were pooled.
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Our results showed that, in contrast to the previously
employed genetic models, acute pharmacological inhibition did
not alter NK cell identity suggesting differential requirements
for acquisition of signature genes vs. homeostasis. Moreover,
except for Bcl2, the impact of JAK inhibition on NK
cells appeared to be cumulative during the time frame
analyzed and encompassed effects on cell cycle as well
as survival.
Redundant Effects of Tofacitinib on the
Transcriptional States and Functions of
ILC1 and NK Cells
To discriminate possible mechanisms underlying the differential
sensitivity to JAKinibs on the homeostatic pool of liver ILC1
and NK cells, we explored the impact of tofacitinib on
the transcriptome of ILC1 (Supplemental Table 2). Similar to
what observed in NK cells, transcriptomic changes in ILC1
mainly consisted of a reduction in gene expression (Figure 3A,
and Supplemental Table 2). Among the few significantly up-
regulated genes, only Tcf7, a transcription factor expressed
by ILC progenitors and required for the development of the
whole ILC compartment (34), reached high expression levels
of 54 RPKM and a FC higher than 2. Similarly to what we
observed in NK cells, genes involved in survival (Bcl2), function
(Gzmb), and proliferation (Mki67) were mainly down-regulated
in ILC1.
To define distinct and shared genes affected by JAK inhibition
on ILC1 and NK cells, we compared the two datasets highlighting
the genes up- and down-regulated in ILC1 (FC > 2; p-value
< 0.05). As shown in Figure 3B, most of the genes down-
regulated in ILC1 followed a similar trend in NK cells (red
ellipse), including Bcl2, Bcl2l1, or Bspry (Figure 3C, group
1). Moreover, we observed a discrete fraction of genes that
was selectively down-regulated in ILC1 (green box). This
group was enriched with genes specifically expressed on ILC1.
Among these genes, Cish, which encodes for cytokine-inducible
SH2 containing protein (CIS), was constitutively expressed on
ILC1 and decreased upon in vivo treatment with tofacitinib
(Figure 3C, group 2). Among the up-regulated genes, Bcl6 was
also induced in NK cells; and vice-versa, genes up-regulated in
NK cells, such as, Fos and Jun followed a similar trend in ILC1
(Figure 3C, group 3).
Gene ontology (GO) analysis showed that transcripts
regulating the response to cytokines/virus, cell cycle and the
apoptotic pathway were enriched among the tofacitinib targets
in ILC1 (Figure 3D). Thus, we sought to measure whether
administration of tofacitinib for 7 days differentially affected the
ability to produce IFN-γ, as well as, the expression of Ki67 and
Bcl2 in liver ILC1 and NK cells. To evaluate the production
of IFN-γ, liver cells were isolated both from untreated and
tofacitinib-treated mice and stimulated with PMA/Ionomycin,
IL-2/IL-12, or IL-12/IL-18. As shown in Figure 4A, a 7-days
treatment with tofacitinib reduced the ability of NK cells to
produce IFN-γ upon PMA/Ionomycin stimulation, while the
potential of NK cells and ILC1 to respond to cytokines was
not altered. These data suggest that the pharmacological block
has limited effects on the cell intrinsic abilities to produce
IFN-γ (Figure 4A).
Next, we tracked the levels of Ki67 and Bcl2 expression on
liver ILC1 and NK cells after 7-days treatment with tofacitinib.
Contrary to the impact observed on the homeostatic pools of
both subsets, tofacitinib inhibited Ki67 expression at greater
degree in ILC1 than in NK cells (Figure 4B). As shown above
for splenic NK cells, the effects of tofacitinib on liver ILC1 were
already detectable at day 3 and greater at day 7 after treatment
(Supplemental Figure 3A). These data provide evidence for the
role of JAKinbs in regulating the overall proliferative states of
both ILC1 and NK cells, in vivo. Relative to Bcl2 expression, we
observed that tofacitinib inhibited this protein in both subsets
(Figure 4C). However, the expression levels of Bcl2 in liver
ILC1 isolated from both untreated and tofacitinib-treated mice
exceeded those observed in untreated NK cells, suggesting that
the relatively high levels of Bcl2 on ILC1 might be responsible
for the limited effect of JAKinibs on the homeostatic pool of
these cells.
Altogether, we showed that the effects of JAK inhibition on
ILC1 and NK cells appeared redundant at the transcriptional and
functional level, with genes involved in survival and proliferation
being mainly affected.
Basal Expression Levels of Bcl2 Are Linked
to the Outcome of JAKinibs on the
Homeostatic Numbers of ILC1 and NK
Cells
The impact of Bcl2 family members in regulating NK cell survival
has been previously addressed using genetic models, which have
demonstrated that Bcl2 and Mcl1 have non-redundant roles in
regulating NK cell survival (35–37), while Bcl2l1 is dispensable
(35). In NK cells, Bcl2 is down-regulated when STAT5 signaling
is altered (25, 38), and its overexpression can rescue the effects
on the NK cell pool associated with Stat5 deficiency (39). In
our dataset, the antiapoptotic genes Bcl2 and Bcl2l1 were both
downregulated in ILC1 and NK cells, while Mcl1 expression
was not altered by tofacitinib treatment, implying differential
mechanisms of homeostatic regulation for these three members
of the Bcl2 family.
Given that Bcl2 protein was expressed at higher levels
by liver ILC1, from both untreated and tofacitinib-treated
mice, compared to untreated NK cells, we hypothesized that
the differential effect of tofacitinib on the size of the two
subsets was dependent on their distinct ability to survive
after perturbation of Bcl2 function. To test this hypothesis,
we treated mice with oral administration of a Bcl2 specific
blocker, namely ABT-199 (Venetoclax) for 7 days (40, 41).
We first analyzed whether the pharmacological block of Bcl2
had parallel effects compared with those observed in genetic
models by evaluation the impact of ABT-199 on splenic
NK cells. As shown in Figure 5A, ABT-199 administration
induced a global decrease of the number of splenic NK cells.
In addition, treatment mainly affected the number of more
differentiated subsets defined according CD27 and CD11b
expression (Figure 5B). These observations were in line with the
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FIGURE 4 | Impact of tofacitinib treatment on the functions of NK cells and ILC1. (A) Bar graphs show the percentage of IFN-γ-positive ILC1 and NK cells, quantified
by flow cytometry, after 2 h stimulation with PMA/Ionomycin (P/I), or 6 h stimulation with IL-2/IL-12 or IL-12/IL-18, in mice treated or not for 1 week with tofacitinib.
Two experiments were combined. (B) Percentage of Ki67-positive ILC1 and NK cells isolated from liver after 7 days administration of tofacitinib or vehicle.
(C) Representative histogram plots (left panel) and bar graphs (MFI, right panel) show Bcl2 protein expression in ILC1 and NK cells from mice treated with tofacitinib or
vehicle. *P < 0.05; ***P < 0.001.
FIGURE 5 | ABT-199 treatment differentially affects the homeostatic pool of liver ILC1 and NK cells. Mice were dosed orally with ABT-199 or vehicle daily for 7 days.
(A) Relative cell numbers of splenic NK cells and (B) NK cell subsets (dissected based on CD27 and CD11b expression) are shown. (C) Liver ILC1 and NK cells in
mice untreated or treated for 7 days with ABT-199 (Venetoclax) or vehicle are depicted. Two experiments were combined (vehicle n = 8; ABT-199 n = 6), and values
were normalized to the mean of vehicle-treated mice for each corresponding experiment. One-way ANOVA was applied. *P < 0.05; **P < 0.01; ***P < 0.001.
low Bcl2 expression levels observed in mature CD11b+ NK cell
subsets (Supplemental Figure 3B) and with previous evidence in
mice showing major defects in mature NK cells associated with
the ablation of Bcl2 gene.
Having established the impact of ABT-199 administration
on splenic NK cells, we next analyzed its effect on the liver
subsets. As shown in Figure 5C, treatment with ABT-199 led to
a significant decrease of both liver ILC1 and NK cells. However,
the number of the NK cell pool was affected at a higher degree
in comparison to the number of ILC1, indicating that the higher
levels of Bcl2 present on ILC1 provided an advantage in term of
survival as compared to NK cells.
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Altogether we showed that pharmacological inhibition of Bcl2
in mice recapitulated the effects observed using genetic models
targeting Bcl2, consisting in a major loss of more differentiated
NK cells. Moreover, we provided evidence for a differential effect
of Bcl2 inhibition in ILC1 and NK cells, the latter being more
sensitive to ABT-199 treatment.
DISCUSSION
To better understand the impact of JAK inhibition in regulation
of NK cells and ILC homeostasis, we have administered JAKinibs
to mice at doses comparable to the range approved for clinical
use. The first unexpected finding we observed was the differential
impact of JAKinibs on the homeostasis of NK cells and ILC1.
This was unanticipated because both subsets were highly affected
when Jak3 and Stat5 were targeted by genetic approaches in
mice (20, 25). Mechanistically, we speculated that the limited
effect of JAKinibs on the pool of ILC1 was linked to their
higher expression levels of Bcl2 compared to NK cells. This
hypothesis is supported by the higher sensitivity of NK cells
compared to ILC1, in respect to the pharmacological block
of Bcl2.
Along with survival, the cell cycle of both NK cells and ILC1
was highly affected by tofacitinib treatment; the drastic reduction
of cells in the G1-S-M phase associated with the low frequency of
Ki67+ cells outline the pivotal role of JAK signals in regulating
the proliferation of these prototypical subsets in vivo, and can
also contribute to the decrease of their homeostatic number.
Interestingly, this aspect, although inferred by results obtained
using in vitro systems, had remained unexplained by employing
genetic approaches, in vivo.
The effects observed on the pool of bone marrow NK
cells and their precursors represent another possible factor
contributing to the to the decreased number of NK cells
in other organs. In this regard, tofacitinib treatment induces
an increase of the chemokine receptor CXCR4, which could
alter mechanisms of bone marrow retention of NK cells (42,
43). Despite the differences on the homeostatic numbers, the
effect of JAK inhibition at the transcriptional level was similar
for both NK cells and ILC1, with a main reduction of the
expression of JAK-targets. No major changes in genes defining
the NK cell identity were observed, indicating a differential
role for JAK-dependent signals in regulating acquisition of
identity and homeostasis. Among the few upregulated genes,
we found the transcription factors Bcl6, Tcf1, Fos, and Jun.
These TFs could be usually repressed by JAK-signals or,
alternatively, up-regulated after tofacitinib treatment allowing
cells to adapt to deprivation of JAK-dependent signals. The
expression of Bcl6 has been related to mechanisms of ILC
plasticity, involving suppression of ILC3 genes and promotion
of NK/ILC1 specific programs (44). Although transitions of
NK cells toward an ILC1-like phenotype occur both under
physiological and pathological conditions, we did not observe
alterations of ILC1 markers, such as Trail and CD49a,
in NK cells after treatment (data not shown). Thus, the
higher expression of Bcl6 in both NK cells and ILC1 after
tofacitinib treatment might be part of a circuit reinforcing
NK/ILC1 phenotypes in absence of proper levels of JAK-
dependent signals.
While most of the genes followed a common transcriptional
trend in NK cells and ILC1 upon tofacitinib treatment, Cish
represented one of the few exceptions, being differentially
targeted by tofacitinib in the two type 1 subsets. As
recently reported, the homeostatic expression of Cish is
very low in NK cells but increases rapidly following IL-
15 stimulation (45). Since Cish levels were downregulated
after in vivo treatment with tofacitinib, the constitutive
expression of Cish in ILC1, instead, could be dependent on
the high levels of JAK-dependent signals acting on these
tissue-resident cells.
Moreover, we noticed that most of the effects observed
in NK cells at day 7 after treatment were also present at an
earlier time point. However, the impact of JAK inhibition
on NK cells appeared to be cumulative, within the time
frame analyzed, in terms of cell numbers, maturation
stages and proliferation, with Bcl2 representing the only
exception. Thus, our data suggest that the limited effects of
tofacitinib on NK cell transcriptome could be independent
from mechanisms of adaptation occurring during the
treatment, which may select or generate cells resistant to
JAK inhibition.
Finally, our study showed that this approach represents both
an opportunity to better understand ILC biology as well as
a strategy to modulate ILC functions during diseases. Since
pharmacological inhibition of JAKs is now successfully utilized
for the treatment of several immune-mediated pathologies, our
study sheds light on the potential effects on immune cells when
this pathway is targeted.
DATA AVAILABILITY STATEMENT
The datasets generated for this study can be found in the
GEO: GSE135116.
ETHICS STATEMENT
The animal study was reviewed and approved by National
Institute of Arthritis and Musculoskeletal and Skin Diseases,
Institutional Animal Care and Use Committee (IACUC).
AUTHOR CONTRIBUTIONS
LV performed the in vitro, in vivo, and RNA-seq experiments.
ML, NG, CL, JK, GP, SD, and YF helped to perform
the experiments. SB processed the transcriptomic data and
performed the computational analyses. GS performed the
transcriptomic analysis and data visualization. JO’S contributed
to the project design, data interpretation, and manuscript
writing. CT provided the critical reagents and helped to write
the paper. LV, GS, and MG designed the project and wrote the
manuscript with input from all authors.
Frontiers in Immunology | www.frontiersin.org 8 December 2019 | Volume 10 | Article 2972
Vian et al. JAK Signals Regulate NK-ILC1 Homeostasis
FUNDING
This work was supported by the Intramural Research Program
of the National Institute of Arthritis and Musculoskeletal and
Skin Diseases (ZIG AR041168-12; ZIC AR041169-12; ZIH
AR041173-12, ZIC AR041181-11, and 1 ZIC AR041207-04).
CT gratefully acknowledges support from the NCATS and
NCI intramural programs. GS was supported by the Italian
Association for Cancer Research (AIRC), MFAG 2018 (Project
Code: 21311); and Institut Pasteur (France), Transversal
Research Program; PTR-113-17.
ACKNOWLEDGMENTS
We would like to thank Dr. Yohei Mikami for critical reading
the manuscript.
SUPPLEMENTARY MATERIAL




1. O’Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses.
Immunity. (2008) 28:477-87. doi: 10.1016/j.immuni.2008.03.002
2. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK
inhibition as a therapeutic strategy for immune and inflammatory diseases.
Nat Rev Drug Discov. (2017) 16:843-62. doi: 10.1038/nrd.2017.201
3. Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl
G, et al. Innate lymphoid cells: 10 years on. Cell. (2018) 174:1054-
66. doi: 10.1016/j.cell.2018.07.017
4. Spits H, Bernink JH, Lanier L. NK cells and type 1 innate lymphoid cells:
partners in host defense.Nat Immunol. (2016) 17:758-64. doi: 10.1038/ni.3482
5. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate
lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol.
(2013) 13:145-9. doi: 10.1038/nri3365
6. Sojka DK, Tian Z, Yokoyama WM. Tissue-resident natural
killer cells and their potential diversity. Semin Immunol. (2014)
26:127-31. doi: 10.1016/j.smim.2014.01.010
7. Lim AI, Di Santo JP. ILC-poiesis: ensuring tissue ILC differentiation
at the right place and time. Eur J Immunol. (2018) 49:11-
8. doi: 10.1002/eji.201747294
8. Zhang J, Marotel M, Fauteux-Daniel S, Mathieu A-L, Viel S, Marçais A, et al.
T-bet and eomes govern differentiation and function of mouse and human
NK cells and ILC1. Eur J Immunol. (2018) 48:738–50. doi: 10.1002/eji.2017
47299
9. Sciumè G, Le MT, Gadina M. HiJAKing innate lymphoid Cells? Front
Immunol. (2017) 8:438. doi: 10.3389/fimmu.2017.00438
10. Moodley D, YoshidaH,Mostafavi S, Asinovski N, Ortiz-Lopez A, Symanowicz
P, et al. Network pharmacology of JAK inhibitors. Proc Natl Acad Sci USA.
(2016) 113:9852-7. doi: 10.1073/pnas.1610253113
11. Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez J-B, Dowty ME,
et al. The mechanism of action of tofacitinib-an oral Janus kinase inhibitor for
the treatment of rheumatoid arthritis. Clin Exp Rheumatol. (2016) 34:318-28.
12. Schönberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana
S, Cornez I, Hejazi M, et al. JAK inhibition impairs NK cell
function in myeloproliferative neoplasms. Cancer Res. (2015)
75:2187-99. doi: 10.1158/0008-5472.CAN-14-3198
13. Valenzuela F, Papp KA, Pariser D, Tyring SK, Wolk R, Buonanno M,
et al. Effects of tofacitinib on lymphocyte sub-populations, CMV and
EBV viral load in patients with plaque psoriasis. BMC Dermatol. (2015)
15:8. doi: 10.1186/s12895-015-0025-y
14. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators
and effectors of immunity and tissue remodeling. Nat Immunol. (2011)
12:21-7. doi: 10.1038/ni.1962
15. Huntington ND. The unconventional expression of IL-15 and its role in NK
cell homeostasis. Immunol Cell Biol. (2014) 92:210-3. doi: 10.1038/icb.2014.1
16. Leonard WJ, Lin J-X, O’Shea JJ. The γc family of cytokines:
basic biology to therapeutic ramifications. Immunity. (2019)
50:832-50. doi: 10.1016/j.immuni.2019.03.028
17. Stabile H, Scarno G, Fionda C, Gismondi A, Santoni A, Gadina M, et al.
JAK/STAT signaling in regulation of innate lymphoid cells: the gods before
the guardians. Immunol Rev. (2018) 286:148-59. doi: 10.1111/imr.12705
18. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations
of Jak-3 gene in patients with autosomal severe combined immune deficiency
(SCID). Nature. (1995) 377:65-8. doi: 10.1038/377065a0
19. Vély F, Barlogis V, Vallentin B, Neven B, Piperoglou C, Ebbo M, et al.
Evidence of innate lymphoid cell redundancy in humans. Nat Immunol.
(2016) 17:1291-99. doi: 10.1038/ni.3553
20. Robinette ML, Cella M, Telliez JB, Ulland TK, Barrow AD, Capuder K, et al.
Jak3 deficiency blocks innate lymphoid cell development. Mucosal Immunol.
(2018) 11:50-60. doi: 10.1038/mi.2017.38
21. Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD, et al. Stat5a/b
are essential for normal lymphoid development and differentiation. Proc Natl
Acad Sci USA. (2006) 103:1000-5. doi: 10.1073/pnas.0507350103
22. Eckelhart E,WarschW, Zebedin E, SimmaO, Stoiber D, Kolbe T, et al. A novel
Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and
development. Blood. (2011) 117:1565-73. doi: 10.1182/blood-2010-06-291633
23. Witalisz-Siepracka A, Klein K, Prinz D, Leidenfrost N, Schabbauer G, Dohnal
A, et al. Loss of JAK1 drives innate immune deficiency. Front Immunol. (2018)
9:3108. doi: 10.3389/fimmu.2018.03108
24. Imada K, Bloom ET, Nakajima H, Horvath-Arcidiacono JA, Udy
GB, Davey HW, et al. Stat5b is essential for natural killer cell-
mediated proliferation and cytolytic activity. J Exp Med. (1998)
188:2067-74. doi: 10.1084/jem.188.11.2067
25. Villarino A V, Sciumè G, Davis FP, Iwata S, Zitti B, Robinson GW,
et al. Subset- and tissue-defined STAT5 thresholds control homeostasis
and function of innate lymphoid cells. J Exp Med. (2017) 214:2999-
3014. doi: 10.1084/jem.20150907
26. Gadina M, Johnson C, Schwartz D, Bonelli M, Hasni S, Kanno
Y, et al. Translational and clinical advances in JAK-STAT
biology: the present and future of jakinibs. J Leukoc Biol. (2018)
104:499-514. doi: 10.1002/JLB.5RI0218-084R
27. Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, et al.
Tofacitinib ameliorates murine lupus and its associated vascular dysfunction.
Arthritis Rheumatol. (2017) 69:148-60. doi: 10.1002/art.39818
28. Shih HY, Sciumè G, Mikami Y, Guo L, Sun HW, Brooks SR, et al.
Developmental acquisition of regulomes underlies innate lymphoid cell
functionality. Cell. (2016) 165:1120-33. doi: 10.1016/j.cell.2016.04.029
29. Xu H, Jesson MI, Seneviratne UI, Lin TH, Sharif MN, Xue L, et al. PF-
06651600, a Dual JAK3/TEC family kinase inhibitor. ACS Chem Biol. (2019)
14:1235-42. doi: 10.1021/acschembio.9b00188
30. Haan C, Rolvering C, Raulf F, Kapp M, Drückes P, Thoma G,
et al. Jak1 has a dominant role over Jak3 in signal transduction
through γc-containing cytokine receptors. Chem Biol. (2011)
18:314-23. doi: 10.1016/j.chembiol.2011.01.012
31. Bezman NA, Kim CC, Sun JC, Min-Oo G, Hendricks DW, Kamimura Y,
et al. Immunological Genome Project Consortium. Molecular definition of
the identity and activation of natural killer cells.Nat Immunol. (2012) 13:1000-
9. doi: 10.1038/ni.2395
32. Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of
mouse NK cells is a 4-stage developmental program. Blood. (2009) 113:5488-
96. doi: 10.1182/blood-2008-10-187179
33. Crinier A, Milpied P, Escalière B, Piperoglou C, Galluso J, Balsamo A, et al.
High-dimensional single-cell analysis identifies organ-specific signatures and
Frontiers in Immunology | www.frontiersin.org 9 December 2019 | Volume 10 | Article 2972
Vian et al. JAK Signals Regulate NK-ILC1 Homeostasis
conserved NK cell subsets in humans and mice. Immunity. (2018) 49:971-
86.e5. doi: 10.1016/j.immuni.2018.09.009
34. Yang Q, Li F, Harly C, Xing S, Ye L, Xia X, et al. TCF-1 upregulation identifies
early innate lymphoid progenitors in the bone marrow. Nat Immunol. (2015)
16:1044-50. doi: 10.1038/ni.3248
35. Huntington ND, Puthalakath H, Gunn P, Naik E, Michalak EM, Smyth MJ,
et al. Interleukin 15-mediated survival of natural killer cells is determined
by interactions among Bim, Noxa and Mcl-1. Nat Immunol. (2007) 8:856-
63. doi: 10.1038/ni1487
36. Sathe P, Delconte RB, Souza-Fonseca-Guimaraes F, Seillet C, Chopin
M, Vandenberg CJ, et al. Innate immunodeficiency following genetic
ablation of Mcl1 in natural killer cells. Nat Commun. (2014)
5:4539. doi: 10.1038/ncomms5539
37. Viant C, Guia S, Hennessy RJ, Rautela J, Pham K, Bernat C, et al. Cell cycle
progression dictates the requirement for BCL2 in natural killer cell survival. J
Exp Med. (2017) 214:491-510. doi: 10.1084/jem.20160869
38. Lin J-X, Du N, Li P, Kazemian M, Gebregiorgis T, Spolski R, et al.
Critical functions for STAT5 tetramers in the maturation and survival of
natural killer cells. Nat Commun. (2017) 8:1320. doi: 10.1038/s41467-017-
01477-5
39. Gotthardt D, Putz EM, Grundschober E, Prchal-MurphyM, Straka E, Kudweis
P, et al. STAT5 Is a key regulator in NK cells and acts as a molecular
switch from tumor surveillance to tumor promotion. Cancer Discov. (2016)
6:414-29. doi: 10.1158/2159-8290.CD-15-0732
40. O’Steen S, GreenDJ, Gopal AK, Orozco JJ, Kenoyer AL, Lin Y, et al. Venetoclax
synergizes with radiotherapy for treatment of B-cell lymphomas. Cancer Res.
(2017) 77:3885-93. doi: 10.1158/0008-5472.CAN-17-0082
41. Lochmann TL, Floros KV, Naseri M, Powell KM, Cook W, March RJ,
et al. Venetoclax is effective in small-cell lung cancers with high BCL-2
expression. Clin Cancer Res. (2018) 24:360-69. doi: 10.1158/1078-0432.CCR-
17-1606
42. Bernardini G, Sciume G, Bosisio D, Morrone S, Sozzani S, Santoni A. CCL3
and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets.
Blood. (2008) 111:3626-34. doi: 10.1182/blood-2007-08-106203
43. Mayol K, Biajoux V, Marvel J, Balabanian K, Walzer T. Sequential
desensitization of CXCR4 and S1P5 controls natural killer cell trafficking.
Blood. (2011) 118:4863-71. doi: 10.1182/blood-2011-06-362574
44. Pokrovskii M, Hall JA, Ochayon DE, Yi R, Chaimowitz NS, Seelamneni H,
et al. Characterization of transcriptional regulatory networks that promote
and restrict identities and functions of intestinal innate lymphoid cells.
Immunity. (2019) 51:185-197.e6. doi: 10.1016/j.immuni.2019.06.001
45. Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, et al. CIS
is a potent checkpoint in NK cell-mediated tumor immunity. Nat Immunol.
(2016) 17:816-24. doi: 10.1038/ni.3470
Conflict of Interest: The National Institutes of Health hold patents on targeting
JAKs. National Institute of Arthritis and Musculoskeletal and Skin Diseases
(NIAMS) (JO’S and MG) and Pfizer have a Collaborative Research and
Development Award (CRADA).
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2019 Vian, Le, Gazaniga, Kieltyka, Liu, Pietropaolo, Dell’Orso, Brooks,
Furumoto, Thomas, O’Shea, Sciumè and Gadina. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 10 December 2019 | Volume 10 | Article 2972
